{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:35:57Z","timestamp":1770485757763,"version":"3.49.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T00:00:00Z","timestamp":1392163200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0082880","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T16:42:32Z","timestamp":1392223352000},"page":"e82880","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":64,"title":["Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.1371","volume":"9","author":[{"given":"Gijs W. D.","family":"Landman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertruide H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelis J. J.","family":"van Hateren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaas H.","family":"Groenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rijk O. B.","family":"Gans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan T.","family":"Houweling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk J. G.","family":"Bilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanne","family":"Kleefstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"SE Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"ref2","unstructured":"(2008). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"TK Schramm","year":"2011","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.diabres.2008.09.004","article-title":"Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study","volume":"82","author":"SM Sadikot","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.diabres.2009.09.008","article-title":"Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study","volume":"86","author":"M Khalangot","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1475-2840-9-54","article-title":"Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention\u2013a retrospective nationwide cohort study","volume":"9","author":"CH Jorgensen","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1463-1326.2011.01496.x","article-title":"Variations in tissue selectivity amongst insulin secretagogues: a systematic review","volume":"14","author":"AS Abdelmoneim","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1463-1326.2004.00462.x","article-title":"The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes)","volume":"7","author":"P Kardas","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1056-8727(02)00272-6","article-title":"Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions","volume":"17","author":"FM Gribble","year":"2003","journal-title":"J Diabetes Complications"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.CIR.86.1.311","article-title":"Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning","volume":"86","author":"JA Auchampach","year":"1992","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.RES.69.3.571","article-title":"ATP-regulated K+ channels protect the myocardium against ischemia\/reperfusion damage","volume":"69","author":"WC Cole","year":"1991","journal-title":"Circ Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1126\/science.2107575","article-title":"Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels","volume":"247","author":"J Daut","year":"1990","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/0002-9343(91)90420-3","article-title":"Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients","volume":"90","author":"J Gram","year":"1991","journal-title":"Am J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1464-5491.1994.tb00256.x","article-title":"Glibenclamide vs gliclazide in type 2 diabetes of the elderly","volume":"11","author":"D Tessier","year":"1994","journal-title":"Diabet Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","journal-title":"Am J Kidney Dis"},{"key":"ref16","unstructured":"(Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http:\/\/www.cochrane-handbook.org<\/ext-link>.)."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMe048225","article-title":"Clinical trial registration: a statement from the International Committee of Medical Journal Editors","volume":"351","author":"C De Angelis","year":"2004","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMe058127","article-title":"Is this clinical trial fully registered?\u2013A statement from the International Committee of Medical Journal Editors","volume":"352","author":"CD De Angelis","year":"2005","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"T Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1185\/03007998509109650","article-title":"Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas","volume":"9","author":"AD Harrower","year":"1985","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0168-8227(87)80010-4","article-title":"Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study","volume":"3","author":"G Jerums","year":"1987","journal-title":"Diabetes Res Clin Pract"},{"key":"ref22","first-page":"420","article-title":"Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients","volume":"15","author":"A Collier","year":"1989","journal-title":"Diabete Metab"},{"key":"ref23","first-page":"209","article-title":"Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD","volume":"17","author":"J Noury","year":"1991","journal-title":"Diabete Metab"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s005920050151","article-title":"Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients","volume":"36","author":"N Guvener","year":"1999","journal-title":"Acta Diabetol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0026-0495(99)90226-3","article-title":"Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes","volume":"48","author":"D Tessier","year":"1999","journal-title":"Metabolism"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1185\/030079901750120231","article-title":"Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes","volume":"16","author":"S Salman","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1464-5491.2003.01053.x","article-title":"Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents","volume":"20","author":"NJ Furlong","year":"2003","journal-title":"Diabet Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/diacare.27.1.41","article-title":"Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes","volume":"27","author":"JM Lawrence","year":"2004","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2362.2004.01381.x","article-title":"GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients","volume":"34","author":"G Schernthaner","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","article-title":"A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial","volume":"22","author":"BH Charbonnel","year":"2005","journal-title":"Diabet Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","article-title":"Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study","volume":"21","author":"DR Matthews","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1464-5491.2006.01801.x","article-title":"Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes","volume":"23","author":"G Perriello","year":"2006","journal-title":"Diabet Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1464-5491.2006.01914.x","article-title":"Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone","volume":"23","author":"S Ristic","year":"2006","journal-title":"Diabet Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0029-1234042","article-title":"Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes","volume":"41","author":"JE Foley","year":"2009","journal-title":"Hormone and Metabolic Research"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1464-5491.2010.02938.x","article-title":"A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study","volume":"27","author":"C Filozof","year":"2010","journal-title":"Diabetic Medicine"},{"key":"ref36","unstructured":"(2010) Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment. . http:\/\/clinicaltrialsgov\/ct2\/show\/NCT01022762?term=NCT01022762&rank=1<\/ext-link>"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"A Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"S Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00125-008-1147-0","article-title":"Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia","volume":"52","author":"SG Swinnen","year":"2009","journal-title":"Diabetologia"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2008.723","article-title":"Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects","volume":"300","author":"JP Vandenbroucke","year":"2008","journal-title":"JAMA"},{"key":"ref41","first-page":"CD008143","article-title":"Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus","author":"B Hemmingsen","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0082880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:46:26Z","timestamp":1588970786000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0082880"}},"subtitle":[],"editor":[{"given":"Marta","family":"Letizia Hribal","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,12]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0082880","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,12]]}}}